EQS — News: seragy Launches with €12 Million Financing to Advance Quantitative Biomarkers for Neurodegenerative Diseases

EQS-News: seragy holding GmbH / Key word(s): Financing seragy Launches with €12 Million Financing to Advance Quantitative Biomarkers for Neurodegenerative Diseases 14.10.2026 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. ══════════════════════════════════════════════════════════════════════════ seragy Launches with €12 Million Financing to Advance Quantitative Biomarkers for Neurodegenerative Diseases • Development of quantitative biomarker strategies for proteopathies through seragy’s proprietary SeRAS^® technology • Expansion of the company’s laboratory and analytical capabilities with funding from Commerzbank, the Mittelständische Beteiligungsgesellschaft (MBG), and the State of Lower Saxony • Separate funding from The Michael J. Fox Foundation provides support for a quantitative SeRAS-based assay for Parkinson’s disease Hanover, Germany, October 14, 2026 — seragy holding GmbH (formerly Prosperodes GmbH), a biomarker strategy company focused on neurodegenerative diseases and other proteopathies, has secured €12 million in funding to accelerate the development of its SeRAS^® platform (Seed Replication, Analysis and Subtyping) and expand i